Objective: This study was aimed to compare the efficacy and safety of Myo inositol versus Metformin in polycystic ovarian syndrome in women. Study design: A retrospective randomized comparative study. Place and Duration: In Gynaecology and Obstetrics Department of Combined Military Hospital, Peshawar for the period from June, 2020 to November, 2021. Methods: The study was conducted on 100 patients that were randomly divided into two groups of 50 each: group A and group B. Group A was given the treatment: Tab Myoinositol 1gm twice daily and Group B was given: Tab Metformin 500mg thrice daily for six months. While treating women with Polycystic Ovary Syndrome, the efficacy assessment was done on observing menstrual irregularity, clinical (acne, hirsutism), infertility and changes in weight for 6 months. Safety assessment was also done. For statistical analysis, SPSS-20.0 was used. Results: The mean age in group A was 24.6±3.22 years and mean BMI 25.7±4.24 kg/m2 while in group B mean age was 23.12±7.40 years with mean BMI 26.1±4.31 kg/m2. After a period of six months, we found that a significant improvement in all of the symptoms was present in both groups. On the other hand, when looking at the two groups' symptoms at three and six months, there was no discernible difference between them. In terms of its safety profile, myo-inositol came out on top when compared to metformin. Conclusion: Both metformin and myo-inositol have been shown to be effective in treating PCOS. Insulin resistance, irregular menstruation, hyperandrogenism, and infertility are all helped by these medications. Treatments for PCOS were equally effective, relieving symptoms for patients, but a direct comparison showed no clear winner. In comparison to Metformin, myoinositol had a higher rate of patient acceptance. Keywords: PCOS, Infertility, Metformin, Myoinositol, Insulin Resistance, Irregular menstruation
Objective: The study's objective is to examine the effectiveness of syntometrine and oxytocin in actively managing the third stage of labour in order to lower the risk of PPH and other undesirable third stage outcomes. Study Design: Randomized/Prospective study Place and Duration: Gynae & Obs department of Combined Military Hospital Peshawar for the duration from 1st June 2021 to 30th November 2021. Methods: This study comprised of 140 females of third stage labour. Age of the females was 18-40 years. After getting informed written consent detailed demographics of enrolled cases were recorded. Patients were equally divided in two groups. Group I had 70 patients and received syntometrine (5 IU Synthetic Oxytocin and 0.5 mg ergometrine maleate) and in group II oxytocin was given to 70 females. Outcomes among both groups were recorded in terms of blood loss and postpartum hemorrhage. SPSS 23.0 was used to analyze all data. Results: The mean age of the patients was 28.3±6.18 years and had mean BMI 27.6±11.25 kg/m2. Mean gestational age was 36.11±5.19 weeks. Frequency of primigravida was 80 (57.1%). Frequency of emergency delivery was found in 85 (60.7%) cases while 55 (39.3%) females admitted to OPD. 72 (51.4%) females were from rural areas and 67 (47.8%) cases were educated. We found that mean blood loss in group II was higher 165.1±8.66 ml as compared to group I 118.7±9.39 ml with p value <0.005. There was no any PPH found in group I while in group II PPH found in 3 (4.3%) cases. Frequency of hypertension was higher in group I. We found higher number of adverse outcomes among females of syntometrine group as compared to oxytocin group. Conclusion: In this study we concluded that use of syntometrine in third stage of labour was effective and useful in terms of reduction in blood loss and PPH as compared to oxytocin while frequency of adverse events and hypertension was higher in syntometrine group as compared to oxytocin. Keywords: Pregnant Females, Third Stage Labour, Syntometrine, Oxytocin, Blood Loss
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.